Delosia5 mg

Delosia 5 mg is a non-sedating antihistamine prescribed for the relief of symptoms associated with allergic conditions. It is indicated for the treatment of:

• Seasonal and perennial allergic rhinitis — providing relief from sneezing, runny nose (nasal discharge), nasal itching, congestion or stuffiness, and postnasal drip.
• Allergy-related ocular symptoms — including itchy, watery (tearing) and red eyes.
• Upper respiratory allergic symptoms — such as itching of the palate and allergy-associated coughing.
• Chronic idiopathic urticaria (chronic hives) — reducing the intensity of itching (pruritus) as well as the size and number of hives (wheals).

By blocking histamine activity, Delosia 5 mg helps control both nasal and non-nasal symptoms of allergy, improving daily comfort and quality of life for patients with seasonal, year-round, or chronic allergic disorders.

Non-sedating antihistamines

Delosia 5 mg is the major active metabolite of Loratadine. It is a long-acting, non-sedating tricyclic antihistamine that acts as a selective, peripheral histamine H1-receptor antagonist. By competitively binding to peripheral H1-receptors, Delosia 5 mg prevents histamine—one of the key mediators released during an allergic reaction—from triggering the cascade of allergy symptoms such as itching, sneezing, nasal discharge and hives.

In addition to blocking H1-receptors, Delosia 5 mg demonstrates anti-allergic and anti-inflammatory properties, including the inhibition of histamine release from human mast cells. Because it does not readily cross the blood-brain barrier at recommended doses, it produces minimal sedation compared with older, first-generation antihistamines.

Following oral administration, Delosia 5 mg is well absorbed, with plasma concentrations becoming detectable within about 30 minutes. Its long duration of action allows for convenient once-daily dosing, providing 24-hour symptom control. The drug is extensively metabolised in the liver to 3-hydroxyDelosia 5 mg, an active metabolite, and is eliminated via both urine and faeces.

No clinically relevant drug interactions have been reported.

No clinically relevant drug interactions have been reported with Delosia 5 mg in clinical studies. When co-administered with erythromycin, ketoconazole or azithromycin, no clinically significant changes in the plasma concentration or safety profile of Delosia 5 mg were observed.

Delosia 5 mg does not appear to potentiate the sedative effect of alcohol at recommended doses. Nevertheless, to ensure safe use, patients should always inform their doctor or pharmacist of all prescription medicines, over-the-counter products, herbal preparations and supplements they are taking before starting Delosia 5 mg.

Delosia 5 mg is generally well tolerated. Most side effects are mild and less common, and may include:

• Headache
• Nausea
• Fatigue or tiredness
• Dizziness
• Pharyngitis (sore throat)
• Dyspepsia (indigestion)
• Myalgia (muscle pain)
• Dry mouth

Rarely, hypersensitivity reactions such as rash, itching, hives, swelling and, very rarely, anaphylaxis have been reported. Patients who experience severe allergic reactions, palpitations, or any unusual or persistent symptoms should discontinue the medicine and seek medical attention promptly.

Pregnancy (Category C): The safety of Delosia 5 mg during pregnancy has not been firmly established. It should not be used during pregnancy unless clearly necessary and only when the potential benefit to the mother outweighs any possible risk to the foetus, as judged by a physician.

Lactation: Delosia 5 mg passes into breast milk. A decision should therefore be made—together with the treating doctor—whether to discontinue breastfeeding or to discontinue the medication, taking into account the importance of the drug to the mother. Nursing mothers should use Delosia 5 mg only under medical supervision.

Delosia 5 mg should be used with caution in the following situations:

• Hepatic or renal impairment: In adult patients with liver or kidney impairment, a reduced starting dose of one 5 mg tablet every other day is recommended, based on pharmacokinetic data.
• History of seizures: Caution is advised in patients with a personal or family history of seizures (convulsions).

Patients should take the medicine strictly as directed and should not exceed the recommended dose. If symptoms persist or worsen despite treatment, a physician should be consulted for further evaluation.

No clinically relevant adverse effects have been reported following overdose with Delosia 5 mg at doses within the studied range. In the event of a suspected overdose, standard supportive and symptomatic measures should be instituted and continued as required. Patients or caregivers should contact a physician or the nearest emergency department if a significant overdose is suspected.

Store in a cool, dry place, protected from light. Keep the temperature below 30°C. Do not freeze. Keep the medicine in its original packaging and out of the reach and sight of children. Do not use after the expiry date printed on the package.

Delosia 5 mg, in appropriate age-specific dosage forms and doses, is recommended for use in children and adolescents. Pediatric drops and syrup formulations allow accurate dosing for infants and young children, while tablets are intended for children 12 years of age and older and for adults.

In elderly patients and in those with hepatic or renal impairment, dosage adjustment may be required and treatment should be individualised under medical supervision.

Non-sedating antihistamines

Delosia 5 mg, the major active metabolite of Loratadine, is a non-sedating; long acting tricyclic histamine antagonist with selective H1-receptor histamine antagonist activity. Delosia 5 mg also inhibits histamine release from human mast cell.

Pregnancy Category C. The safe use of Delosia 5 mg during pregnancy has not been established. Therefore, Delosia 5 mg is not to be used during pregnancy unless clearly indicated. Delosia 5 mg passes into breast milk, therefore a decision should be made whether to discontinue nursing or to discontinue Delosia 5 mg taking into account the importance of the drug to the mother.

Recommended in the use in children & adolescents.